• Repligen unveiled a deal to buy BioLife Solutions for $31 per share, targeting a close in Q4 2026.
• Consideration totals $11.25 per share in cash, $19.75 per share in Repligen stock; 0.1442 Repligen shares per BioLife share.
• Transaction implies about $1.5 billion enterprise value; funding includes $564 million cash and 7,200,000 Repligen shares.
• Repligen expects more than $20 million of year-one synergies, rising to more than $30 million in year two.
• Repligen flagged Q2 revenue growth of about 12% reported, 13% organic; full results scheduled for July 28, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Repligen Corporation published the original content used to generate this news brief on July 22, 2026, and is solely responsible for the information contained therein.